RxSpan MD NAD+ Review: Routes, Prices, and Visit Fees

RxSpan MD is most interesting for its three NAD+ formats: injection, nasal spray, and flex-dose tablet. Its catalog lists $249 for the base injection or nasal product and $199 for the base tablet. The decision becomes less simple when multi-month packages and the cost of an unsuccessful consultation are included. We would confirm those details before comparing it with a lower-priced monthly offer.

We checked RxSpan's public longevity page, product catalog endpoint, and terms. We did not complete an intake, buy a plan, or assess the clinical service. The prices below come from the provider's public catalog, which we could retrieve even when the initial text of its JavaScript-driven longevity page did not display the products.¹²

A broader choice of format

The public catalog lists NAD+ as an injection, nasal spray, and flex-dose tablet, with separate base and multi-month entries. The injection and nasal base entries are $249; the tablet is $199.² That choice is the clearest reason to investigate RxSpan if a particular route is important to you.

For someone unwilling to self-inject, the tablet is an additional option to discuss alongside a spray. But an oral tablet, nasal preparation, and injection are not merely different packaging for an equally proven outcome. A decision about route needs the clinician's explanation of the exact formulation and the uncertainty around the goal you are trying to achieve.

We would not choose the more expensive route because it sounds stronger, or the cheaper one because it seems easier. Ask what evidence supports the proposed outcome for that preparation, what practical burdens it introduces, and what would make the clinician recommend against using it.

Compare the payment total before the monthly equivalent

The public catalog lists injection packages at $597 for three months, $997 for six, and $1,797 for twelve. Nasal packages are $597, $949, and $1,797. Tablet packages are $549, $949, and $1,797 for the same respective terms.²

Those totals make the comparison more informative than a single starting price. The three-month tablet costs less upfront than the corresponding injection package. By the twelve-month entry, all three list the same total. That does not mean that every package supplies the same amount of NAD+, or that the routes deliver equivalent exposure; the catalog entries do not establish that comparison.

Treat these as the named package prices and confirm how a chosen plan is charged and renewed. We did not verify a final checkout. We would not assume that a catalog field labeled “Month” guarantees calendar-month renewal, or that the next refill necessarily repeats the initial charge. Ask for the term, payment today, next charge date, and amount of medication in one written summary.

An unsuccessful visit can still cost money

RxSpan's public catalog also includes a telehealth-visit description stating an $80 consultation fee if medication is not prescribed. When medication is prescribed, it describes a combined charge covering consultation, medication, and shipping.²

That changes the risk of starting an assessment. A clinician declining treatment may be the right medical outcome, but it may still leave a bill. Before proceeding, ask whether this provision applies to your selected NAD+ plan and exactly when the fee becomes payable. It is a useful question even if a marketing card suggests that a visit is included.

For comparison, read CoreAge's refund review rather than assuming that rejection policies are the same across telehealth brands. A medication refund and a consultation refund are separate promises. Comparing only what happens when a prescription is issued misses the financial outcome for a person who does not qualify.

Who provides care and who dispenses

RxSpan's terms identify RxSpan MD LLC, require users to be at least 18, and describe independent licensed professionals making clinical decisions. They say medication may be fulfilled by licensed pharmacies if prescribed.³ An adult-age platform requirement does not mean that every adult is eligible for NAD+.

The NAD+ catalog descriptions also state that prescribing depends on clinical evaluation and that RxSpan does not manufacture compounded medication.² We could not establish the named dispensing pharmacy for an individual NAD+ order from the pages reviewed. We also did not verify a complete current state-by-state NAD+ availability list.

Those limits matter to a buyer. Ask about availability in your state before spending time on an intake, and request the dispensing pharmacy and actual prescription label details before use. Do not infer access from the fact that a public website loads in your location.

What three routes do not prove

Route choice is a service feature. It does not establish that NAD+ improves concentration, treats brain fog, or slows cognitive aging. The randomized NR trials cited here found no cognitive improvement, despite measuring related biological effects.⁴⁵ NR is a precursor taken orally in those studies; it is not RxSpan's finished tablet, spray, or injection.

That distinction cuts both ways. The trials cannot prove that RxSpan's products have no effect, but they cannot justify a product-specific benefit claim. A clinician should explain what remains uncertain, rather than treating research on a related molecule as an answer about your prescription. Our precursor evidence review explains why the ingredient and endpoint matter.

Compounded medication is also not FDA-approved; the FDA does not review it for safety, effectiveness, or quality before marketing.⁶ This is a category limitation, not a finding of a defect in a particular RxSpan prescription.

Our assessment

RxSpan is a useful comparison option when you want to discuss several delivery formats with a clinician. Its public package totals let you ask concrete cost questions. The drawbacks are the higher base prices, larger upfront commitments, the possible $80 cost without a prescription, and unresolved order-specific pharmacy and supply details.

We would start with the shortest suitable written offer and avoid choosing a long package just to make the monthly equivalent look lower. Ask how discontinuation affects unused prepaid treatment and whether cancellation stops future billing immediately or at a later renewal. Those answers should arrive before payment, not after you discover the plan is unsuitable.

If your main goal is clearer thinking, consult the NAD+ evidence review before comparing formats on the provider board. Our provider review library also covers Enhance MD as another offer to compare before choosing an oral format. A wider catalog is convenient. It should not distract from establishing the cause of symptoms and the evidence for addressing them.